Y-mAbs Therapeutics continues to advance cancer treatment with innovative antibody therapeutics, despite market fluctuations, and is poised to make significant contributions to oncology.

Y-mAbs Therapeutics Inc. has reported strong first-quarter financial results, exceeding expectations and reaffirming its outlook for the fiscal year, setting the stage for future growth in the biotechnology sector.

Y-mAbs Therapeutics Inc has delivered a strong first-quarter financial performance, surpassing market expectations and reaffirming its full-year outlook, solidifying its position as a leader in the biotechnology sector.